Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
Tags: amphoteric, Bendeka®, cancer, chemotherapy, chronic lymphocytic leukemia (CLL), DNA alkylating agent, multiple myeloma, non-Hodgkin's lymphoma, Treanda®
BASi Method Number SAP.1907
Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.
